Ferdja Ferdja.com delivers the latest news and relevant information across various domains including politics, economics, technology, culture, and more. Stay informed with our detailed articles and in-depth analyses.
By Andrew Silver
SHANGHAI (Reuters) – A second Chinese language drugmaker has utilized for approval to promote a generic model of Novo Nordisk’s blockbuster diabetes drug Ozempic in China.
Livzon Pharmaceutical Group stated this week its subsidiary was looking for approval to promote the drug to manage blood sugar in sufferers with sort 2 diabetes and cut back threat of main opposed cardiovascular occasions in those that even have heart problems.
Novo’s Ozempic gross sales in China greater than doubled final yr to 4.8 billion Danish crowns ($694 million), accounting for five% of its whole international Ozempic gross sales, and the corporate expects approval for its associated weight-loss drug Wegovy later this yr.
Novo’s patent in China for semaglutide, the energetic ingredient utilized in each Ozempic and Wegovy, is ready to run out in 2026.
The drugmaker is within the midst of a authorized combat within the nation over the patent and an opposed court docket ruling might make it lose its semaglutide exclusivity even sooner.
Livzon is considered one of a number of native companies creating their very own variations of semaglutide-based medication and is the second to use on the market after Hangzhou Jiuyuan Gene Engineering earlier this yr.
Livzon’s submitting to the Shenzhen inventory change didn’t disclose efficacy knowledge and the corporate didn’t reply to a Reuters request for the knowledge. The group has accomplished a section three medical trial, in accordance with a trial database.
Livzon stated that its analysis and improvement on semaglutide injection to this point had value 141.4 million yuan ($19.5 million).
($1 = 7.2540 Chinese language yuan renminbi)
(Reporting by Andrew Silver; Modifying by Miyoung Kim and Mrigank Dhaniwala)
